Home Blog Page 230

Alibaba Cloud Expands European Footprint with Two Availability Zones in France

A suite of Agentic AI services set to launch for European customers later this year


PARIS, FRANCE – Media OutReach Newswire – 17 June 2026 – Alibaba Cloud, a leading global provider of AI infrastructure and the intelligence backbone of Alibaba Group, today announced the launch of its cloud region in France. Featuring two availability zones, this launch addresses accelerating demand from European customers across key sectors – including retail, software development, AI-powered creative platforms, and sports tech – for advanced cloud and digital solutions located in Europe. The new facilities in Paris mark Alibaba Clouds third European hub, complementing its existing infrastructure in Germany and the UK.

The France region delivers a comprehensive suite of enterprise-grade cloud computing services, spanning elastic computing, storage, containerization, networking, security, databases, and advanced developer tools. Built with strict data privacy and sovereignty in mind, the infrastructure adheres to rigorous European regulatory frameworks and standards, including data privacy, cybersecurity, resilience, and sovereignty.

Now fully operational, the France region equips European businesses with high availability, operational resilience, and robust disaster recovery capabilities. This launch expands Alibaba Clouds global network to 105 availability zones across 32 regions, reinforcing its commitment to providing a secure, scalable, and sustainable foundation for global digital innovation.

To meet the growing demand for enterprise agents, Alibaba Cloud plans to launch a suite of agentic AI services in European markets in the second half of this year. The lineup includes AgentRun, a one-stop development platform for AI agents; STAROps, a comprehensive intelligent operations platform; ACS Agent Sandbox, which provides hardware-level security isolation while reducing operational costs of AI agents; Agent Security Center, which ensures agent build-time integrity and supply chain transparency; AI Security Guardrails 2.0, designed for safe model interactions, local compliance, and runtime risk interception; and Agentic SOC, a solution enabling automated threat response and closed-loop auditing. These products are designed to streamline the development and operation of enterprise-scale agents within a secure environment, offering full lifecycle management from development and debugging to deployment, real-world operations, and end-to-end security protection.

“The expansion of our cloud infrastructure into France reinforces our ongoing commitment to empowering European businesses with sovereign, secure, and intelligent solutions,” said Dr. Feifei Li, Chief Technology Officer and President of International Business of Alibaba Cloud. “This expansion, alongside the introduction of our agentic AI services to Europe, aligns with our broader strategy to bring our full-stack AI+Cloud ecosystem to global customers as we enter the agentic era.”

Alibaba Cloud has served European markets since 2016, supporting prominent multinationals in expanding globally while helping local businesses stay competitive. For example, SAP collaborates with Alibaba to jointly accelerate enterprise innovation and digital transformation, with an initial focus on the China market and a rollout planned for Southeast Asia, the Middle East and Africa. Additionally, Alibaba Cloud has been working with local technology partners to deliver tailored cloud and digital solutions across Europe.

During the Olympic Games Paris 2024, Alibaba Cloud served as the Worldwide Olympic Partner and Official Cloud Service Provider, driving the digital transformation of the Games through its cloud and AI innovation. Notably, in partnership with Olympic Broadcasting Services (OBS), Alibaba Cloud launched OBS Cloud 3.0. The initiative made the work of OBS and Media Rights-Holders (MRHs) easier and more efficient, and delivering of live signals over OBS Live Cloud became the main method of remote distribution to broadcasters for the first time in the history of the Olympic Games.

In May 2026, Alibaba announced a multi-year partnership with the Union of European Football Associations (UEFA) and UC3, the joint venture between UEFA and European Football Clubs (EFC) that controls and manages the strategic marketing, sales, and delivery of commercial rights for UEFA club competitions. The partnership, starting immediately with UEFA and in 2027 with UC3, will see the deployment of Alibaba’s advanced AI capabilities to support fan engagement and media and content management via its Qwen Large Language Model (LLM). Together with its cloud computing infrastructure and global e-commerce platform, Alibaba will power an immersive fan and content experience worldwide across UEFA’s flagship men’s competitions.

Alibaba Cloud’s expanded presence in Europe underscores its unwavering commitment to driving digital innovation in the region. By providing local businesses with leading AI+Cloud solutions to efficiently build, deploy, and manage AI agents, Alibaba Cloud aims to accelerate their transition from traditional automation to agent-led intelligent operations. At its recent international Qwen Conference, the company unveiled major updates across its foundation models, AI infrastructure, cloud-native tools, and enterprise agent products, helping global enterprises rapidly deploy practical AI agents into day-to-day business environments.

Hashtag: #AlibabaCloud

The issuer is solely responsible for the content of this announcement.

About Alibaba Cloud

Alibaba Cloud (https://www.alibabacloud.com/) is a global leader in full-stack AI+Cloud solutions. It offers a comprehensive suite of flexible, scalable and secure cloud services built on a three-tiered architecture of Infrastructure-as-a-Service (IaaS), Platform-as-a-Service (PaaS) and Model-as-a-Service (MaaS). Alibaba Cloud empowers enterprises worldwide with its full-stack AI capabilities, powered by Qwen (Chinese: Qianwen), a family of large language and multimodal AI models developed by Alibaba. Debuted in 2023, Qwen models are available to global developers via HuggingFace (open-weight) or through API on Model Studio, Alibaba’s one-stop, enterprise-grade AI development platform offering access to the full suite of Qwen foundation models.

Lao Gin Claims Top Honor at 2026 International Competition

This photo is used for representational purpose only.

A gin from Laos received a Gold Outstanding medal, the highest distinction, at the 2026 International Wine & Spirit Competition (IWSC), placing it among only ten gins worldwide to reach the top tier this year.

Gin is a distilled spirit flavored primarily with juniper berries alongside a range of botanicals, produced by distilling a neutral spirit with those flavoring ingredients. According to the IWSC, the gin brand named Lao Gin, a 750ml Contemporary Gin from The Lao Distilling Company, impressed judges with a palate described as “silky and creamy, with zingy, zesty notes,” scoring 98 points. 

Founded in 2022, the company has built its reputation on locally sourced ingredients, turning native botanicals and local traditions into something genuinely distinctive on the world stage.

The IWSC, founded in 1969 and held annually in London, is one of the most respected drinks competitions in the world, covering spirits, wine, beer, cider, and sake. 

This year, judges awarded 233 medals across Silver, Gold, and Gold Outstanding tiers, with only ten gins reaching the top Gold Outstanding. Alongside Lao Gin in the Contemporary category were Tanqueray No. Ten Gin from Scotland, Aureus Vita Gin from England, and Taiwan Coriander Superb Craft Gin. 

Classic Gin top honors went to Navy Gin from New Zealand, Juniper Freak Gin from Australia, and Ohoro Standard Gin from Japan. Wood-Finished Gin winners were Awildian Coromandel Mānuka Gin from New Zealand and Barrel-Aged Gin from Japan, while Haskap Gin from Canada was the sole Flavored Gin winner.

Lao Gin’s result places it alongside established global names including Tanqueray No. Ten Gin, Aureus Vita Gin from Krenngala Meurth Distilling Company, and Taiwan Coriander Superb Craft Gin, as well as craft producers from New Zealand, Australia, Canada, and Japan

All ten winners now advance to trophy consideration ahead of the organization’s annual awards ceremony in London in November later this year.

Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026

HONG KONG, June 17, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. Ligufalimab is Akeso’s proprietary next-generation humanized IgG4 anti-CD47 monoclonal antibody. The study evaluated ligufalimab in combination with azacitidine (AZA) and venetoclax (VEN) in patients with treatment-naïve acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Ligufalimab-based combination therapy demonstrates a significant trend toward survival benefit

  • At a median follow-up of 10 months in the ligufalimab group and 8.8 months in the control group, median event-free survival (EFS) was 9.1 months in the ligufalimab group versus 6.9 months in the control group (hazard ratio [HR] = 0.46). The 6-month EFS rate was 67.8% versus 55.5% in the control group, and the 9-month EFS rate was 53.2% versus 14.1%.
  • Median overall survival (mOS) was not reached in the ligufalimab group versus 8.3 months in the control group (HR = 0.46). The 6-month OS rate was 83.3% versus 73.2%, and the 9-month OS rate was 78.7% versus 43.1% in the control group.

Ligufalimab-based combination therapy yields deep tumor responses

  • The objective response rate (ORR) was 80.0% in the ligufalimab group versus 66.7% in the control group, and the composite complete response (CRc) rate was 56.7% versus 53.3%; the proportion of patients achieving CRc with minimal residual disease (MRD) negativity was higher in the ligufalimab group than in the control group (46.7% vs. 36.7%).
  • The median duration of CRc was 10.4 months in the ligufalimab group, which was markedly superior to 5.6 months in the control group.

Favorable Safety Profile With No New Safety Signals Observed

  • The incidence of overall treatment-emergent adverse events (TEAEs) and serious adverse events was comparable between treatment arms. The most common TEAEs were generally consistent with those expected in the context of AML and AZA+VEN therapy.
  • Anemia occurred in 46.7% of patients in the ligufalimab arm versus 50.0% in the control arm.

Notably, ligufalimab has already received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of AML. Akeso is advancing its ligufalimab clinical development programs at a globally competitive pace across both hematologic malignancies and solid tumors. Ligufalimab is also the first anti-CD47 monoclonal antibody worldwide to enter a registrational Phase III clinical trial in solid tumors.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

TAT and Agoda Expand Strategic Collaboration to Drive Tourism Growth in Thailand

BANGKOK, June 17, 2026 /PRNewswire/ — Digital travel platform Agoda and Tourism Authority of Thailand (TAT) have reaffirmed their strategic collaboration to strengthen Thailand’s position as a leading global tourism destination through data-driven marketing initiatives, tourism product development, and industry capacity-building efforts.

Representatives of Agoda and TAT celebrate the MOU Launch
Representatives of Agoda and TAT celebrate the MOU Launch

The collaboration combines Agoda’s travel insights and digital expertise with TAT’s destination marketing capabilities to support demand generation from international markets while encouraging domestic tourism in Thailand.

Areas of collaboration include promoting Thailand’s unique tourism offerings, highlighting emerging trends such as wellness tourism and encouraging travel to lesser-known destinations. The partnership will also support broader industry development through encouraging more sustainable practices and capacity-building initiatives under the ongoing Trusted Thailand collaboration.

Omri Morgenshtern, Chief Executive Officer at Agoda said “We see many opportunities to work together on TAT’s priorities, from highlighting wellness travel as the new luxury to amplifying communications around travel safety. Our joint efforts will promote Thailand’s rich and trusted offerings to travelers around the globe.”

Thapanee Kiatphaibool, Governor of Tourism Authority of Thailand added, “Our partnership with Agoda enables us to develop targeted campaigns that showcase Thailand’s rich cultural heritage, diverse tourism experiences and strong commitment to visitor satisfaction. By leveraging digital innovation and market intelligence, we can better connect with travelers worldwide and further reinforce Thailand’s reputation as a premier travel destination.”

Founded in Phuket, Thailand over two decades ago, Agoda maintains strong ties to Thailand and continues to support the country’s tourism sector through its global digital travel platform, which offers access to more than 6 million accommodation properties, 130,000 flight routes, and 300,000 travel activities worldwide.

Techman Robot Targets Southeast Asian Smart Manufacturing Markets at Thailand Automation Show

AI-guided smart cartoning & packing lines and the all-new lightweight TM3S cobot make their overseas debut.

BANGKOK, June 17, 2026 /PRNewswire/ — Techman Robot, a global leader in collaborative robots and AI vision technology, will showcase its latest innovations at the “ME Assembly & Automation 2026”. Centered around the dual themes of “Smart Packaging Automation” and “High-Efficiency AI Inspection,” the company is introducing tailored solutions for the electronics manufacturing, automotive components, food & beverage, and consumer electronics sectors

AI Vision-Guided Smart Cartoning and Packing Line
AI Vision-Guided Smart Cartoning and Packing Line

AI Vision-Guided Smart Cartoning and Packing Line

To address the critical automation demands within e-commerce and retail product packaging, Techman Robot is highlighting its “Automated Cartoning and Packing Line”. This solution overcomes the traditional limitations of mechanical grippers in complex packaging environments by integrating Techman collaborative robot, advanced AI vision guidance systems, and dexterous gripping technologies.

Demonstrating a seamless synergy of “brain, eye, and hand,” the system automates cardboard fetching, precise positioning, box folding, cartoning, and transport. Featuring a modular design and rapid deployment capabilities, this solution significantly reduces line footprint, shortens implementation timelines, and enhances packaging efficiency and operational stability—making it ideal for high-mix, low-volume agile production.

The All-New Lightweight TM3S Cobot

Techman Robot is also debuting its latest flagship model, the brand-new “TM3S” collaborative robot. Engineered for on-site operations requiring frequent relocation and high flexibility, the TM3S boasts an ultra-lightweight design, weighing in at just 12 kilograms.

A key feature of the TM3S is its “Quick-release Connector” for cabling, which enables production engineers to install, disassemble, and relocate the unit within an exceptionally short timeframe, vastly improving operational mobility on the shop floor. Furthermore, the TM3S carries forward the signature feature of the Techman Robot family: the “Integrated Vision” system. This provides the robot with advanced spatial awareness and positioning capabilities, making it particularly suited for high-precision welding, assembly, workstation localization, and automated rapid inspection.

AI Flying Trigger Inspection & Instant Palletizer Solutions

Beyond its packaging and lightweight innovations, Techman Robot is demonstrating its “Flying Trigger AI Inspection” and “Instant Palletizer” systems.

  • Flying Trigger AI Inspection: Allows robots to perform real-time defect inspection and cosmetic recognition while in motion without pausing, driving significant leaps in both throughput and quality control.
  • Instant Palletizer: Offers a streamlined setup and intuitive operation to help Southeast Asian food & beverage and 3C retail clients rapidly upgrade their end-of-line logistics and stacking efficiency, directly addressing regional labor shortages.  

APAC healthcare systems face growing strain as rising patient expectations collide with stretched clinical workforce – Bain & Company survey

  • 95% of consumers want a single touchpoint to manage their healthcare
  • 84% of consumers expect greater convenience from healthcare system
  • Three in four consumers comfortable with AI-enabled healthcare apps
  • One in five doctors actively considering leaving their current employer due to burnout

SINGAPORE, June 17, 2026 /PRNewswire/ — Asia-Pacific healthcare systems are facing growing strain as rising patient expectations collide with a stretched clinical workforce, accelerating the shift toward new care models and AI-enabled support, according to Bain & Company’s 2026 Asia-Pacific Front Line of Healthcare Report.

The report, based on surveys of 6,300 consumers across nine Asia-Pacific markets and 600 doctors in the region, reveals widening tensions across the healthcare system: Consumer expectations are rising faster than experience can keep up, clinicians are ready to walk away from overburdened systems, and AI capabilities are outpacing organizational readiness.

Consumers across Asia-Pacific are increasingly taking a proactive role in managing their health while expecting more convenience, responsiveness and coordination from the healthcare system. Today, 84% of consumers expect greater convenience from the healthcare system, while 71% expect doctors to be more responsive through channels such as phone, WhatsApp or email. Three out of five consumers now also schedule regular checkups and screenings, compared to 47% in 2023.

Additionally, consumers are increasingly seeking care beyond traditional hospital settings. On average, 57% of consumers report receiving care in at least one alternative setting, including telehealth, urgent care clinics, walk-in clinics, home-based care and ambulatory surgery centers. The consumer response to growing fragmentation is also becoming clearer, with 95% of respondents saying they want a single touchpoint to manage their healthcare, up from 70% in 2019.

“The region’s healthcare systems are approaching an inflection point where rising demand, workforce scarcity and fragmented care delivery models are converging at the same time,” said Vikram Kapur, head of Bain & Company’s Global Healthcare & Life Sciences practice. “The challenge now is not simply expanding access, but fundamentally redesigning how care is coordinated, delivered and experienced.”

Clinician strain is also intensifying across the region. One in five doctors report actively considering leaving their current employer, driven primarily by excessive workload, lack of recognition and burnout. Around one in three doctors also report significant waste and inefficiency in their daily work, including excessive forms and paperwork, low-value repetitive tasks and delays caused by fragmented workflows and coordination gaps.

AI-enabled care is gaining ground across Asia-Pacific and is showing potential for easing some pressures in healthcare, particularly for use cases that support clinicians and improve efficiency. Doctors, surveyed by Bain, identify reducing administrative burden and workload as the most significant potential benefits of AI adoption. Nearly three in four Asia-Pacific consumers report feeling comfortable with at least one AI-enabled healthcare application.

However, the report also highlights that the human relationship within care delivery remains highly valued. In-person appointments continue to be the preferred channel for non-acute symptoms, and both consumers and doctors view telehealth as a complement to, rather than a substitute for, in-person care. Approximately one in three doctors also report that their organizations are not prepared to deploy AI at scale, citing unclear strategy, limited training and insufficient clinician involvement as key barriers.

“Consumers and clinicians are increasingly open to AI-enabled support, but technology alone will not resolve the structural pressures facing healthcare systems,” added Kapur. “The organizations best positioned to lead will be those that combine AI-enabled transformation with stronger care coordination and deeper clinician engagement.”

The report identifies five strategic opportunities for healthcare stakeholders across the region:

  • Become a trusted coordination point for your customers: Own the patient relationship end-to -end across settings and channels.
  • Redesign care journeys around the moments that matter most: Recognize the economic value of customer experience and put it at the heart of strategy.
  • Implement the principles of value-based care models: Build the operational foundations to capture value as payment models shift from volume to outcomes.
  • Treat AI as a business transformation: Embed AI deeply into core operating models and redesign workflows, rather than layering it onto broken processes.
  • Increase clinician engagement: Deliver a better clinician experience and equip the clinical workforce to lead the transformation ahead.

The 2026 Asia-Pacific Front Line of Healthcare Report surveyed consumers in Australia, Mainland China, Hong Kong, India, Indonesia, Malaysia, the Philippines, Singapore and Vietnam, as well as doctors in Australia and the Philippines.

Media contacts:
Ann Lee (Singapore) — ann.lee@bain.com
Rachel Ng (Kuala Lumpur) — rachel.ng@bain.com
Gary Duncan (London) — gary.duncan@bain.com
Dan Pinkney (Boston) — dan.pinkney@bain.com 

About Bain & Company

Bain & Company works with leaders worldwide to solve their toughest challenges and deliver enduring results. Since 1973, we’ve partnered with clients, including private equity and portfolio companies, to build the capabilities they need to stay ahead of change and help them redefine their industries. We measure our success by our clients’ success, and we proudly hold the highest levels of client advocacy in our field.

Bain is consistently recognized globally as one of the best places to work. We operate as one global team, uniting strategists, industry and functional experts, technologists, and advisors with a vibrant ecosystem of technology partners.

Notes to Editors

Bain & Company was founded in 1973 and today has 19,000 employees across 67 cities in 40 countries. We have worked with more than two-thirds of the Global 500 and more than 9,000 companies worldwide. Bain has pledged to deliver $2 billion in pro bono consulting to nonprofit, public-sector and charitable organizations by 2035. The firm is consistently recognized as a Leader in major analyst rankings across multiple areas, including digital business, innovation, strategy, experience design, customer experience, and carbon-zero transformation.

Daicel DURAST(R) POM Fine Powder Adopted for Innovative Stick-form Lubricant

OSAKA, Japan, June 17, 2026 /PRNewswire/ — Daicel Corporation’s High Performance Polymers (HPPs) SBU (formerly Polyplastics Co., Ltd.), a global leader in engineering plastics, has announced that its DURAST(R) POM fine powder has been adopted for use in an innovative stick-form lubricant produced by Japan-based Maia Co. Ltd. This groundbreaking solid lubricant, utilizing newly launched DURAST(R) POM fine powder, resolves issues such as dripping, splattering, and waste caused by over-application, dramatically transforming maintenance processes.

Image: https://cdn.kyodonewsprwire.jp/prwfile/release/M100475/202606080534/_prw_PI1fl_wFrl551J.png

Maia’s unique manufacturing technology, called Sol – Mid (TM), delivers a product that is typically packaged in a stick-shaped container and can also be molded into custom shapes to meet customer needs. The performance of Sol – Mid (TM) is underpinned by the chemical properties of DURAST(R) POM. This product is formed by mixing ultra-high molecular weight polyethylene (UHMW-PE) with grease. DURAST(R) POM acts as an interlayer between the PE and the grease, and plays a crucial role in maintaining compatibility.

With the stick format, there is no risk of leakage like with liquids, and because it is easy to carry, it offers greater convenience at maintenance sites for office equipment and industrial machinery. For the maintenance of office equipment, it can reduce the use of conventional maintenance oil by approximately 80%.

Previously, the processing of general-purpose resins into uniform powder using conventional grinding methods was extremely difficult. Daicel overcame this challenge by developing a proprietary manufacturing process for DURAST(R) POM, which features a distinctive shape and controlled, fine and sharp particle size distribution.

This stick format solution utilizing DURAST(R) POM is scheduled for full-scale commercialization by targeting maintenance applications for major office equipment manufacturers, in addition to industrial sectors such as industrial machinery repair, bicycle maintenance and conveyor systems.

For more information, visit: https://hpps.daicel.com/global/s/ourapproach/a5nRB000004Rt2vYAC/261?language=en_US

About Daicel Corporation High Performance Polymers SBU: https://kyodonewsprwire.jp/attach/202606080534-O1-pu6X2g4H.pdf 

DURAST(R) is a registered trademark of Daicel Corporation in Japan and other countries.

Vientiane Logistics Park Highlights Regional Connectivity Vision at China-South Asia Exposition 2026

A picture of the 10th China-South Asia Exposition (CSAE 2026) showcasing in Kunming, China. (Photo by VLC)

Vientiane Logistics Park (VLP) showcased its latest infrastructure developments and integrated logistics services at the 10th China-South Asia Exposition (CSAE 2026) in Kunming, China, reinforcing its role in supporting regional trade and connectivity.

The event brought together businesses, investors, and government representatives from across Asia, providing a platform for VLP to present its vision for strengthening Laos’ position as a regional logistics and trade hub.

A key highlight of the event was the signing of a comprehensive Laos-China cooperation agreement, held as part of celebrations marking the 65th anniversary of diplomatic relations between the two countries.

The agreement covers four strategic sectors: new energy equipment, cross-border supply chain logistics and bonded warehousing, integrated trade, and digital finance.

According to VLP, the partnership represents another step forward in expanding economic cooperation between Laos and China while supporting industrial development and regional integration.

The company said the agreement shows a shared commitment to leveraging Laos’ strategic location to strengthen cross-border trade, improve logistics efficiency, and attract greater investment into the country.

As one of Laos’ key logistics infrastructure projects, VLP continues to support the government’s vision of transforming the country from land-locked to land-linked by enhancing regional connectivity and facilitating the movement of goods across international markets.

Through ongoing partnerships and infrastructure development, VLP aims to further position Vientiane as an important gateway for trade, logistics, and investment in the Greater Mekong region.